StockMarketWire.com - Biotechnology company Tiziana Life Sciences said it was speeding up the development of a treatment for the novel coronavirus.
The company said it was expediating the development of TZLS-501, a monoclonal antibody that could help patients with severe lung damage.
Tiziana said it planned to administer TZLS-501 'using a proprietary formulation technology'.
It had in 2017 entered into a worldwide license for composition-of-matter of TZLS-501 with Swiss company Novimmune.
At 9:11am: [LON:TILS] Tiziana Life Sciences Plc share price was +80.5p at 112.5p
Story provided by StockMarketWire.com
Shares Magazine
Shares is the leading weekly publication for retail investors. It is packed with investment ideas, news and educational material to help build and run portfolios and get more from your money.
Investor Events
Shares puts on free Investor Events throughout the year across the country. They provide an opportunity for investors to learn more about companies on the stock market and hear from a range of investment experts including fund managers and Shares journalists.